Mylan Launches Generic Paxil CR
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.
You may also be interested in...
Generic Exclusivity Battles Now Extend To Brand-Authorized Versions: Mylan Blocks Launch Of Apotex's Paxil CR Copy
A court issued a temporary restraining order against Apotex and GlaxoSmithKline in response to Mylan's claims that it has sole rights to market generic Paxil CR under a licensing agreement with GSK.
Generic Exclusivity Battles Now Extend To Brand-Authorized Versions: Mylan Blocks Launch Of Apotex's Paxil CR Copy
A court issued a temporary restraining order against Apotex and GlaxoSmithKline in response to Mylan's claims that it has sole rights to market generic Paxil CR under a licensing agreement with GSK.
Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement
Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.